Inflammatory arthritis genetic risk scores to predict treatment patterns in rheumatoid arthritis
Arthritis & Rheumatology · 20.11.2026
DOI: 10.1002/art.70399 ↗Kurz gefasst
Fachartikel in der Zeitschrift Arthritis & Rheumatology, online erschienen am 20.11.2026. Verfasst von Gregory C McDermott und 18 weiteren Autor:innen.
Abstract (Originalsprache)
Background
Choosing optimal biologic and targeted synthetic DMARD (b/tsDMARD) regimens for individual RA patients can be challenging. This study used electronic health records and linked genotyping data from two large biobanks to investigate genetic factors associated with RA treatment patterns.
Methods
We identified RA patients initiating b/tsDMARDs and with available genotyping data in the Million Veteran Program (MVP) and Mass General Brigham (MGB) Biobank. We used mixture Markov modeling to identify patterns of b/tsDMARD use. We calculated inflammatory arthritis genetic risk scores (GRS) for RA, spondyloarthritis, psoriatic arthritis, lupus, and gout and examined the association of the GRS with b/tsDMARD treatment pattern using logistic regression.
Results
Among 2,454 RA patients in the MVP and 461 patients in the MGB Biobank, we identified common patterns of b/tsDMARD use: TNFi persisters, TNFi to abatacept, and multi‐bDMARD cyclers. In the meta‐analysis, a higher RA GRS was associated with higher odds of belonging to the TNFi to abatacept group (OR 1.129 95%CI 1.008‐1.264 per GRS standard deviation) and multi‐b/tsDMARD cycling (1.137 95%CI 1.056‐1.223) compared to TNFi‐persisters. The spondyloarthritis GRS was associated with a lower odds belonging to multi‐b/tsDMARD (OR 0.824 95%CI 0.762‐0.892) or TNFi to abatacept (OR 0.883 95%CI 0.786‐0.992) patterns compared to TNFi persisters.
Conclusions
Among patients with RA, we observed common patterns of b/tsDMARD use in two separate healthcare systems. Moreover, these patterns had different underlying genetic associations. Higher RA GRS was associated with lower odds of TNFi persistence, while a higher SpA GRS was associated with higher odds of TNFi persistence.
Zitieren
APA
McDermott, G. C., Xiong, X., Posner, D., Cui, J., Panickan, V., Sangar, R., Morini, S., Cagan, A., Jeffway, M., Costa, L., Matty, R., Karlson, E., Ho, Y., Raychaudhuri, S., Cho, K., Knevel, R., Duan, R., Cai, T., & Liao, K. P. (2026). Inflammatory arthritis genetic risk scores to predict treatment patterns in rheumatoid arthritis. Arthritis & Rheumatology. https://doi.org/10.1002/art.70399
Vancouver
McDermott GC, Xiong X, Posner D, Cui J, Panickan V, Sangar R, et al. Inflammatory arthritis genetic risk scores to predict treatment patterns in rheumatoid arthritis. Arthritis & Rheumatology. 2026. doi:10.1002/art.70399
BibTeX
@article{McDermott2026,
author = {McDermott, Gregory C and Xiong, Xin and Posner, Daniel and Cui, Jing and Panickan, Vidul and Sangar, Rahul and Morini, Sara and Cagan, Andrew and Jeffway, Mary and Costa, Lauren and Matty, Rachael and Karlson, Elizabeth and Ho, Yuk‐Lam and Raychaudhuri, Soumya and Cho, Kelly and Knevel, Rachel and Duan, Rui and Cai, Tianxi and Liao, Katherine P},
title = {Inflammatory arthritis genetic risk scores to predict treatment patterns in rheumatoid arthritis},
journal = {Arthritis & Rheumatology},
year = {2026},
doi = {10.1002/art.70399}
}
EUVIMED